Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Free Cash Flow of -$40.9 million for Q1 2026, down 49.09% sequentially from -$27.4 million in Q4 2025, and down 85.56% YoY from -$283.2 million in Q1 2025.
Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Free Cash Flow for 7 years, with the latest figure at -$40.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 85.56% year-over-year to -$40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$112.7 million (down 34.63% YoY) and the FY2025 annual result came in at -$93.8 million, down 14.99% from the prior year.
- Free Cash Flow slipped to -$40.9 million in Q1 2026 per TSHA's latest filing, from -$27.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$5.9 million in Q4 2022 and troughed at -$41.0 million in Q1 2022.
- A 5-year average of -$23.7 million and a median of -$21.8 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 87.91% in 2022, then sank 233.44% in 2023.
- Over 5 years, Free Cash Flow stood at -$5.9 million in 2022, then tumbled by 233.44% to -$19.6 million in 2023, then climbed by 6.43% to -$18.3 million in 2024, then slumped by 49.87% to -$27.4 million in 2025, then slumped by 49.09% to -$40.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$40.9 million, -$27.4 million, and -$23.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | -40.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.78 Mn |
| Jun 30, 2026 | -40.78 Mn |
| Mar 31, 2026 | -40.90 Mn |
| Mar 31, 2026 | -40.90 Mn |
| Dec 31, 2025 | -27.44 Mn |
| Dec 31, 2025 | -27.44 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Jun 30, 2025 | -20.57 Mn |
| Jun 30, 2025 | -20.57 Mn |
| Mar 31, 2025 | -22.04 Mn |
| Mar 31, 2025 | -22.04 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Sep 30, 2024 | -21.55 Mn |
| Sep 30, 2024 | -21.55 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -19.94 Mn |
| Mar 31, 2024 | -19.94 Mn |